Re point 1...I think you are short changing the bio marker data on page 15.  That page has data on all 1212 drugged patients and not just on the low eGFR patients.  Except for eGFR, the remaining bio markers are all going the right way.  Also, on page 19, all the data makes sense (except for the higher LDL sub group).  In short, our drug delivered on almost all metrics.

But your point is just as critical...particularly considering that the eGFR data for all patients on our drug actually FELL and the placebo group ROSE!   I think this data needs double checking...there seems to be an inherent contradiction.